<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients - Stern, A - 2014 | Cochrane Library</title> <meta content="Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients - Stern, A - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005590.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients - Stern, A - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005590.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005590.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients" name="citation_title"/> <meta content="Anat Stern" name="citation_author"/> <meta content="Rambam Health Care Campus" name="citation_author_institution"/> <meta content="a_shteren@rambam.health.gov.il" name="citation_author_email"/> <meta content="Hefziba Green" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Mical Paul" name="citation_author"/> <meta content="Rambam Health Care Campus" name="citation_author_institution"/> <meta content="Liat Vidal" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Leonard Leibovici" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD005590.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005590.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005590.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005590.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Immunocompromised Host; Anti‐Infective Agents [adverse effects, *therapeutic use]; HIV Seronegativity; Pneumonia, Pneumocystis [*prevention &amp; control]; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005590.pub3&amp;doi=10.1002/14651858.CD005590.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005590\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005590\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005590.pub3",title:"Prophylaxis for Pneumocystis pneumonia (PCP) in non\\u2010HIV immunocompromised patients",firstPublishedDate:"Oct 1, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005590.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005590.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005590.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005590.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005590.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005590.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005590.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005590.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005590.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005590.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>23684 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005590.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/appendices#CD005590-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/table_n/CD005590StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/table_n/CD005590StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#CD005590-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Anat Stern</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#CD005590-cr-0003">Hefziba Green</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#CD005590-cr-0004">Mical Paul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#CD005590-cr-0005">Liat Vidal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information#CD005590-cr-0006">Leonard Leibovici</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information/en#CD005590-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005590.pub3">https://doi.org/10.1002/14651858.CD005590.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005590-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005590-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005590-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005590-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005590-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005590-abs-0001" lang="en"> <section id="CD005590-sec-0001"> <h3 class="title" id="CD005590-sec-0001">Background</h3> <p>Pneumocystis pneumonia (PCP) is a disease affecting immunocompromised patients. PCP among these patients is associated with significant morbidity and mortality. </p> </section> <section id="CD005590-sec-0002"> <h3 class="title" id="CD005590-sec-0002">Objectives</h3> <p>To assess the effectiveness of PCP prophylaxis among non‐HIV immunocompromised patients; and to define the type of immunocompromised patient for whom evidence suggests a benefit for PCP prophylaxis. </p> </section> <section id="CD005590-sec-0003"> <h3 class="title" id="CD005590-sec-0003">Search methods</h3> <p>Electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2014, Issue 1), MEDLINE and EMBASE (to March 2014), LILACS (to March 2014), relevant conference proceedings; and references of identified trials. </p> </section> <section id="CD005590-sec-0004"> <h3 class="title" id="CD005590-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or quasi‐RCTs comparing prophylaxis with an antibiotic effective against PCP versus placebo, no intervention, or antibiotic(s) with no activity against PCP; and trials comparing different antibiotics effective against PCP among immunocompromised non‐HIV patients. We only included trials in which Pneumocystis infections were available as an outcome. </p> </section> <section id="CD005590-sec-0005"> <h3 class="title" id="CD005590-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed risk of bias in each trial and extracted data from the included trials. We contacted authors of the included trials to obtain missing data. The primary outcome was documented PCP infections. Risk ratios (RR) with 95% confidence intervals (CI) were estimated and pooled using the random‐effects model. </p> </section> <section id="CD005590-sec-0006"> <h3 class="title" id="CD005590-sec-0006">Main results</h3> <p>Thirteen trials performed between the years 1974 and 2008 were included, involving 1412 patients. Four trials included 520 children with acute lymphoblastic leukemia and the remaining trials included adults with acute leukemia, solid organ transplantation or autologous bone marrow transplantation. Compared to no treatment or treatment with fluoroquinolones (inactive against Pneumocystis), there was an 85% reduction in the occurrence of PCP in patients receiving prophylaxis with trimethoprim/sulfamethoxazole, RR of 0.15 (95% CI 0.04 to 0.62; 10 trials, 1000 patients). The evidence was graded as moderate due to possible risk of bias. PCP‐related mortality was also significantly reduced, RR of 0.17 (95% CI 0.03 to 0.94; nine trials, 886 patients) (low quality of evidence due to possible risk of bias and imprecision), but in trials comparing PCP prophylaxis against placebo or no treatment there was no significant effect on all‐cause mortality (low quality of evidence due to imprecision). Occurrence of leukopenia or neutropenia and their duration were not reported consistently. No significant differences in overall adverse events or events requiring discontinuation were seen comparing trimethoprim/sulfamethoxazole to no treatment or placebo (four trials, 470 patients, moderate quality evidence). No differences between once daily versus thrice weekly trimethoprim/sulfamethoxazole were seen (two trials, 207 patients). </p> </section> <section id="CD005590-sec-0007"> <h3 class="title" id="CD005590-sec-0007">Authors' conclusions</h3> <p>Given an event rate of 6.2% in the control groups of the included trials, prophylaxis for PCP using trimethoprim/sulfamethoxazole is highly effective among non‐HIV immunocompromised patients, with a number needed to treat to prevent PCP of 19 patients (95% CI 17 to 42). Prophylaxis should be considered for patients with a similar baseline risk of PCP. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005590-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005590-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005590-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005590-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005590-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005590-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005590-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005590-abs-0002" lang="en"> <h3>Antibiotic treatment for the prevention of Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients </h3> <p><i>Pneumocystis jiroveci</i> is a fungus causing pneumonia mainly among patients with an impaired immune system, such as those infected with the human immunodeficiency virus (HIV), cancer patients, following organ transplantation, and patients receiving immune suppressive medications. Previous evidence shows that preventive antibiotic treatment (before the onset of the disease) could reduce mortality and morbidity from PCP among patients with HIV. We assessed whether this is also true for immunocompromised non‐HIV patients. </p> <p>The patients included in the 13 trials we identified were adults with acute leukemia or solid organ transplantation and children with acute leukemia. This review of randomised controlled trials (RCTs) found that prophylaxis with trimethoprim/sulfamethoxazole, an antibiotic effective against PCP, significantly reduced the occurrence of PCP by 85%. We found no evidence for a reduction in all cause mortality. Confidence in the results for PCP was moderate to high, while for mortality it was low due to paucity of data. Preventive treatment was not associated with an increased rate of adverse events. Trimethoprim/sulfamethoxazole may be administered thrice weekly as effectively as once daily. </p> <p>Based on our results, the number of people that need to be treated with trimethoprim/sulfamethoxazole for a prolonged period of time (ranging between several weeks to three years in the included trials) in order to prevent one episode of PCP infection was 19; when PCP infection occurs at a rate of about 6% without prophylaxis. Given the low rate of adverse events, prophylaxis should be considered for patients at similar risk of PCP. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005590-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005590-sec-0089"></div> <h3 class="title" id="CD005590-sec-0090">Implications for practice</h3> <section id="CD005590-sec-0090"> <p>Our review shows that TMP/SMX prophylaxis is highly effective for prevention of PCP in patients with hematological malignancies, bone marrow transplantation and solid organ transplantation, both for children and adults. The overall prevalence of severe adverse events with TMP/SMX was low and did not result in treatment discontinuations. Given the observed efficacy of TMP/SMX with regard to PCP prevention, prophylactic TMP/SMX should be considered when the risk of PCP is above the rate we observed (6.2% overall). Clinical conditions in which the rates of PCP for patients not receiving prophylaxis might be above 6.2% include the following (<a href="./references#CD005590-bbs2-0078" title="RodriguezM , FishmanJA . Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus‐negative immunocompromised patients. Clinical Microbiology Reviews2004;17:770‐82. ">Rodriguez 2004</a>). </p> <p> <ul id="CD005590-list-0010"> <li> <p>Allogeneic bone marrow transplantation, during the six months post‐transplantation and afterwards with continued immunosuppression. </p> </li> <li> <p>Solid organ transplantation, in the first six months after transplantation.</p> </li> <li> <p>Acute lymphoblastic leukemia.</p> </li> </ul> </p> <p>The PCP incidence is probably lower for most patients with solid malignancies. Patients receiving corticosteroids for primary or metastatic brain tumours may be at a higher risk warranting prophylaxis (<a href="./references#CD005590-bbs2-0083" title="SepkowitzKA . Pneumocystis carinii pneumonia in patients without AIDS. Clinical Infectious Diseases1993;17 Suppl 2:S416‐22. ">Sepkowitz 1993</a>). Among patients with collagen vascular diseases, only Wegener's granulomatosis has been associated with PCP rates above 2.5%. Quantitative incidence or relative risk data are lacking for patients treated with corticosteroids for chronic lung disease, inflammatory bowel disease, dermatological conditions or other conditions. Similarly, incidence data are lacking for acute myeloid leukemia, treatment with anti‐TNF agents, and newer biological treatments for hematological malignancies. During outbreaks of PCP among immunocompromised patients the incidence of PCP might be high enough to justify prophylaxis. </p> <p>Using the data from our review and data available from studies conducted among HIV‐positive patients, TMP/SMX may be administered thrice weekly as the efficacy is similar to once daily administration. The adult dose of TMP/SMX most commonly administered in our review was 160/800 mg. </p> </section> <h3 class="title" id="CD005590-sec-0091">Implications for research</h3> <section id="CD005590-sec-0091"> <p>Treatment with steroids for more than a month, in a dose equivalent to 20 mg of prednisone or more, may be a risk factor for the development of PCP (<a href="./references#CD005590-bbs2-0088" title="YaleSH , LimperAH . Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clinics Proceedings1996;71:5‐13. ">Yale 1996</a>). Patients with collagen vascular diseases or inflammatory bowel disease receiving other immunosuppressive medication (including anti‐TNFalfa antibodies) are also at risk. Trials are needed for this large population of patients. Documentation of the actual adverse event rate associated with prophylaxis in clinical practice, especially leukopenia, will assist future decisions regarding prophylaxis in immunocompromised patients. The effect of prophylaxis on Pneumocystis resistance should be assessed in longitudinal studies or when TMP/SMX prophylaxis is used in practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005590-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005590-sec-0022"></div> <div class="table" id="CD005590-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients<br/> <b>Settings:</b> <br/> <b>Intervention:</b> TMP/SMX versus placebo, no treatment or non‐PCP drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TMP/SMX versus placebo, no treatment or non‐PCP drug</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Documented PCP infections</b> <br/> Clinical and microbiological criteria<br/> Follow‐up: 1‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1000<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (2 to 39) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (0 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cause mortality ‐ TMP/SMX versus placebo or no treatment</b> <br/> Follow‐up: 2‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.58</b> <br/> (0.17 to 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>461<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (5 to 62) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCP‐related mortality</b> <br/> Clinical only </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (1 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.17</b> <br/> (0.03 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment</b> <br/> Clinical and laboratory criteria and treatment discontinuations </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (1 to 27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> <br/> (0.05 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomisation methods were not described in most trials and only half were blinded.<br/> <sup>2</sup> No serious inconsistency (I<sup>2</sup> = 0%).<br/> <sup>3</sup> Small trials with few events (11 deaths in total), unpowered to examine the effects of prophylaxis on mortality. Pooled effect ranges from no benefit to benefit.<br/> <sup>4</sup> Broad 95% CI for pooled effect (RR 0.03‐0.94) but always below 1.<br/> <sup>5</sup> Broad 95% CI ranging from less to more adverse events with prophylaxis. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005590-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005590-sec-0023"></div> <section id="CD005590-sec-0024"> <h3 class="title" id="CD005590-sec-0024">Description of the condition</h3> <p><i>Pneumocystis jirovecii</i> is a ubiquitous, species‐specific fungus. Infection with <i>Pneumocystis jirovecii</i> is common and occurs at an early age. Serologic surveys have shown nearly universal seropositivity to Pneumocystis by two years of age (<a href="./references#CD005590-bbs2-0087" title="VargasSL , HughesWT , SantolayaME , UlloaAV , PonceCA , CabreraCE , et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clinical Infectious Diseases2001;32:855‐61. ">Vargas 2001</a>). Primary infection is probably largely asymptomatic (<a href="./references#CD005590-bbs2-0063" title="WalzerPD , SmulianAG . Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377‐90. ">Mandel 2010</a>). Colonization with PCP is common, documented to occur in more than 50% of the general adult population, and is assumed to represent re‐infections through person‐to‐person transmission or environmental re‐exposures rather than re‐activation (<a href="./references#CD005590-bbs2-0056" title="GigliottiF , WrightTW . Pneumocystis: where does it live?. PLoS Pathogens2012;8(11):e1003025. ">Gigliotti 2012</a>; <a href="./references#CD005590-bbs2-0073" title="PonceCA , GalloM , BustamanteR , VargasSL . Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clinical Infectious Diseases2010;50(3):347‐53. ">Ponce 2010</a>). Symptomatic, tissue invasive disease is rare and limited to immunocompromised individuals, mainly patients with human immunodeficiency virus infection (HIV) before immune reconstitution. The most common manifestation is Pneumocystis pneumonia (PCP). Common symptoms of PCP include progressive shortness of breath, nonproductive cough, and low‐grade fever. Physical examination often reveals tachypnea, tachycardia, and normal or near‐normal findings on lung ausculation. Hypoxemia is found in most patients. In HIV patients the clinical presentation is usually subtle, despite high organism load, and the mortality rate is 10% to 20% (<a href="./references#CD005590-bbs2-0063" title="WalzerPD , SmulianAG . Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377‐90. ">Mandel 2010</a>; <a href="./references#CD005590-bbs2-0068" title="MorrisA , NorrisKA . Colonization by Pneumocystis jirovecii and its role in disease. Clinical Microbiology Reviews2012;25(2):297‐317. ">Morris 2012</a>). In contrast, among non‐HIV patients PCP typically presents with an abrupt onset of respiratory failure. The mortality rate among non‐HIV patients is 30% to 60%, with a greater risk of death amongst cancer patients in part related to delays in diagnosis (<a href="./references#CD005590-bbs2-0063" title="WalzerPD , SmulianAG . Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377‐90. ">Mandel 2010</a>; <a href="./references#CD005590-bbs2-0068" title="MorrisA , NorrisKA . Colonization by Pneumocystis jirovecii and its role in disease. Clinical Microbiology Reviews2012;25(2):297‐317. ">Morris 2012</a>). In a retrospective study of Pneumocystis infections at Beth Israel Deaconess Medical Center, admissions to the intensive care unit (ICU), mechanical ventilation and mortality rates were 10%, 7% and 10% among HIV patients versus 69%, 66% and 39% among non‐HIV patients (<a href="./references#CD005590-bbs2-0064" title="MansharamaniNG , GarlandR , DelaneyD , KozielH . Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV‐associated cases to other immunocompromised states. Chest2000;118:704‐11. ">Mansharamani 2000</a>). </p> <p>The incidence of PCP among HIV patients in developed countries has decreased with the advent of highly active antiretroviral therapy and prophylaxis, although it remains the most prevalent opportunistic infection in this population (<a href="./references#CD005590-bbs2-0068" title="MorrisA , NorrisKA . Colonization by Pneumocystis jirovecii and its role in disease. Clinical Microbiology Reviews2012;25(2):297‐317. ">Morris 2012</a>). Conversely, the incidence of PCP in immunocompromised patients without HIV is increasing (<a href="./references#CD005590-bbs2-0068" title="MorrisA , NorrisKA . Colonization by Pneumocystis jirovecii and its role in disease. Clinical Microbiology Reviews2012;25(2):297‐317. ">Morris 2012</a>). Patients at risk include cancer patients receiving chemotherapy, bone marrow and solid organ transplant recipients, and other patients treated with corticosteroids or other immune suppressive medications. </p> </section> <section id="CD005590-sec-0025"> <h3 class="title" id="CD005590-sec-0025">Description of the intervention</h3> <p><i>Pneumocystis jirovecii,</i> despite its classification as a fungus, is susceptible to several antibacterial and antiparasitic drugs that can be used for prevention of infection among patients at high risk for PCP. The agent most commonly used for prophylaxis is trimethoprim/sulfamethoxazole (TMP/SMX). Other agents that have activity against <i>Pneumocystis jirovecii</i> include dapsone, pentamidine, atovaquone, pyrimethamine, sulfadoxine, and clindamycin and primaquine in combination. All these drugs can cause side effects that may counterbalance the benefits of PCP prevention. TMP/SMX can cause mild to severe skin rash (up to the life threatening reactions of Stevens‐Johnson syndrome or toxic epidermal necrolysis). Leukopenia (a decrease in the white blood cell count) induced by TMP/SMX may adversely affect patients with hematological cancer. Liver and renal dysfunction may be detrimental to solid organ transplant recipients. The common side effects of dapsone are hemolysis and methemoglobinemia. Hypersensitivity can be life‐threatening, as for TMP/SMX. Pentamidine must be administered through the aerosolized route and can cause acute reactions during inhalation both for the patient being treated and for bystanders (which include respiratory and cardiac manifestations). </p> <p>While guidelines for PCP prophylaixs among HIV patients (<a href="./references#CD005590-bbs2-0072" title="Panel on Opportunistic Infections in HIV‐Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV‐infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. ">Panel HIV 2013</a>) are specific and universally accepted, there is a lack of consensus on prophylaxis in other immunocompromised people. Current guidelines for patients undergoing stem cell transplantation recommend that allogeneic recipients receive PCP prophylaxis from engraftment until at least six months after the transplantation (<a href="./references#CD005590-bbs2-0086" title="TomblynM , ChillerT , EinseleH , GressR , SepkowitzK , StorekJ , et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biology of Blood and Marrow Transplantation2009;15(10):1143‐238. ">Tomblyn 2009</a>). Some experts initiate PCP prophylaxis prior to transplantation, depending on the underlying disease and the pretransplant conditioning regimens or prior chemotherapy. Prophylaxis is recommended for longer than six months in patients who continue to receive immunosuppressive drugs (<a href="./references#CD005590-bbs2-0086" title="TomblynM , ChillerT , EinseleH , GressR , SepkowitzK , StorekJ , et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biology of Blood and Marrow Transplantation2009;15(10):1143‐238. ">Tomblyn 2009</a>). The rate of PCP in autologous stem cell transplant recipients is much lower than among allogeneic recipients and prophylaxis is recommended only for specific high‐risk populations, such as patients with multiple myeloma, or following treatment with purine analogues or high‐dose corticosteroids. The duration of PCP prophylaxis in this setting has not been evaluated, but common practice is to extend prophylaxis to three to six months post‐transplantation (<a href="./references#CD005590-bbs2-0086" title="TomblynM , ChillerT , EinseleH , GressR , SepkowitzK , StorekJ , et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biology of Blood and Marrow Transplantation2009;15(10):1143‐238. ">Tomblyn 2009</a>). Among other hematologic and solid cancer patients an increased risk of PCP was found in patients with acute lymphoblastic leukemia (ALL), prolonged CD4 counts of less than 200/μL, or long term treatment with steroids. Prophylaxis is recommended for the duration of therapy or until the CD4 count is &gt; 200/μL (<a href="./references#CD005590-bbs2-0071" title="NeumannS , KrauseSW , MaschmeyerG , SchielX , vonLilienfeld‐ToalM . Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology2013;92(4):433‐42. ">Neumann 2013</a>). The risk status is less conclusive in patients treated with standard or salvage regimens for lymphoma, and patients with prolonged neutropenia or acute myeloid leukemia. Some experts suggest prophylaxis for the duration of chemotherapy (<a href="./references#CD005590-bbs2-0071" title="NeumannS , KrauseSW , MaschmeyerG , SchielX , vonLilienfeld‐ToalM . Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology2013;92(4):433‐42. ">Neumann 2013</a>). Guidelines for solid organ transplant recipients recommend anti‐Pneumocystis prophylaxis for all recipients for at least six to 12 months post‐transplant, though longer durations can be considered (<a href="./references#CD005590-bbs2-0065" title="MartinSI , FishmanJA , AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. American Journal of Transplantation2013;13 Suppl 4:272‐9. ">Martin 2013</a>). For lung and small bowel transplant recipients, as well as any transplant patient with a history of prior PCP infection or chronic cytomegalovirus (CMV) disease, lifelong prophylaxis may be indicated (<a href="./references#CD005590-bbs2-0065" title="MartinSI , FishmanJA , AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. American Journal of Transplantation2013;13 Suppl 4:272‐9. ">Martin 2013</a>). In addition, PCP prophylaxis is recommended for kidney transplant recipients for at least six weeks during and after treatment for acute rejection (<a href="./references#CD005590-bbs2-0060" title="KasiskeBL , ZeierMG , ChapmanJR , CraigJC , EkbergH , GarveyCA , et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International2010;77(4):299‐311. ">Kasiske 2010</a>). It is suggested that patients with inflammatory bowel disease receive prophylaxis if treated with three immunomodulatory drugs including a calcineurin inhibitor or anti‐TNF therapy (<a href="./references#CD005590-bbs2-0075" title="RahierJF , Ben‐HorinS , ChowersY , ConlonC , DeMunterP , D'HaensG , et al. European evidence‐based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's &amp; Colitis2009;3(2):47‐91. ">Rahier 2009</a>). Other populations in whom experts suggest considering prophylaxis include (<a href="./references#CD005590-bbs2-0063" title="WalzerPD , SmulianAG . Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377‐90. ">Mandel 2010</a>): </p> <p> <ol id="CD005590-list-0001"> <li> <p>primary immune deficiency diseases;</p> </li> <li> <p>severe protein malnutrition;</p> </li> <li> <p>persistent CD4 counts of less than 200/µL;</p> </li> <li> <p>cytotoxic or immunosuppressive therapy for the treatment of collagen vascular diseases and other disorders; </p> </li> <li> <p>patients given the equivalent of 20 mg of prednisone or more, for more than one month.</p> </li> </ol> </p> </section> <section id="CD005590-sec-0026"> <h3 class="title" id="CD005590-sec-0026">Why it is important to do this review</h3> <p>Since PCP is relatively rare and prevention entails the use of drugs with significant adverse effects, it is important to document the risk‐benefit profile of PCP chemoprophylaxis. It is necessary to define the effects of PCP chemoprophylaxis for the different drugs available and different patient populations at different risk levels for PCP. In the previous version of this review we showed that TMP/SMX results in a 91% reduction in the occurrence of PCP compared to no treatment (95% confidence interval 68% to 98%), with few adverse events reported in the included trials (<a href="./references#CD005590-bbs2-0090" title="GreenH , PaulM , VidalL , LeiboviciL . Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients. Cochrane Database of Systematic Reviews2007, Issue 18(3). [DOI: 10.1002/14651858.CD005590.pub2] ">Green 2007</a>; <a href="./references#CD005590-bbs2-0091" title="GreenH , PaulM , VidalL , LeiboviciL . Prophylaxis of Pneumocystis pneumonia in immunocompromised non–HIV‐infected patients: Systematic review and meta‐analysis of randomized controlled trials. Mayo Clinics Proeedings2007;82(9):1052‐9. ">Green 2007a</a>). We have conducted an update of the aforementioned review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005590-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005590-sec-0027"></div> <p> <ul id="CD005590-list-0002"> <li> <p>To assess the effectiveness of PCP prophylaxis among non‐HIV immunocompromised patients</p> </li> <li> <p>To define the type of immunocompromised patient for whom evidence suggests a benefit for PCP prophylaxis </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005590-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005590-sec-0028"></div> <section id="CD005590-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005590-sec-0030"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) or quasi‐RCTs</p> </section> <section id="CD005590-sec-0031"> <h4 class="title">Types of participants</h4> <p> <ul id="CD005590-list-0003"> <li> <p>Cancer patients (hematological and solid organ malignancy)</p> </li> <li> <p>Bone marrow recipients</p> </li> <li> <p>Solid organ transplant patients</p> </li> <li> <p>Patients receiving corticosteroids</p> </li> <li> <p>Patients receiving other immunosuppressive medications (for connective tissue disease, chronic lung disease, inflammatory bowel disease) </p> </li> <li> <p>Severe malnutrition</p> </li> <li> <p>Primary immune‐deficiency diseases</p> </li> </ul> </p> <p>HIV positive patients were excluded.</p> </section> <section id="CD005590-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Any chemoprophylaxis administered for the prevention of Pneumocystis infections versus placebo, no intervention, or an antibiotic(s) with no activity against Pneumocystis pneumonia. We also included trials that compared different antibiotics for the prevention of Pneumocystis infections. Only trials in which an outcome of Pneumocystis infections was available (in the original report or through correspondence with the authors) were included. We searched specifically for the following antibiotics, which are effective against Pneumocystis in vitro, considered for prophylaxis: </p> <p> <ul id="CD005590-list-0004"> <li> <p>trimethoprim/sulfamethoxazole (TMP/SMX);</p> </li> <li> <p>pentamidine;</p> </li> <li> <p>atovaquone;</p> </li> <li> <p>dapsone;</p> </li> <li> <p>pyrimethamine;</p> </li> <li> <p>clindamycin.</p> </li> </ul> </p> </section> <section id="CD005590-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD005590-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005590-list-0005"> <li> <p>Documented Pneumocystis infections, defined as documentation of Pneumocystis from a properly obtained specimen (bronchoalveolar lavage, induced sputum, or biopsy) in a patient with clinical manifestations compatible with PCP. Accepted methods for documentation included: staining techniques (methenamine silver, Wright‐Giemase, or other), immunofluorescence on clinical specimens or immunohistochemistry on tissue sections and polymerase chain reaction (PCR) (<a href="./references#CD005590-bbs2-0063" title="WalzerPD , SmulianAG . Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377‐90. ">Mandel 2010</a>). </p> </li> </ul> </p> </section> <section id="CD005590-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005590-list-0006"> <li> <p>All cause mortality at end of study follow‐up</p> </li> <li> <p>PCP‐related mortality at end of study follow‐up</p> </li> <li> <p>Infections other than Pneumocystis (bacterial infections specifically)</p> </li> </ul> </p> <section id="CD005590-sec-0036"> <h6 class="title">Adverse effects</h6> <p> <ul id="CD005590-list-0007"> <li> <p>Any adverse event</p> </li> <li> <p>Adverse events requiring temporary or permanent treatment discontinuation</p> </li> <li> <p>Severe adverse events requiring treatment discontinuation: defined as leukopenia, thrombocytopenia or severe dermatological reaction </p> </li> <li> <p>Specific adverse events: any dermatological, any leukopenia</p> </li> <li> <p>Resistance of PCP to antibiotics</p> </li> <li> <p>Resistance of other bacteria to antibiotics</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD005590-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005590-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified studies by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2014, Issue 1), MEDLINE and EMBASE (to March 2014), LILACS (to March 2014), and by handsearching the following conference proceedings: European Congress of Clinical Microbiology and Infectious Diseases (2001 to 2014) and Annual Meeting of the Infectious Diseases Society of America (IDSA) (2001 to 2014). </p> <p>We searched the following trial databases for ongoing and unpublished trials: Current Controlled Trials in the meta‐register of controlled clinical trials (<a href="http://www.controlled-trials.com/" target="_blank">http://www.controlled‐trials.com/</a>); and the National Institutes of Health database (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>). </p> <p>The search strategies are listed in <a href="./appendices#CD005590-sec-0095">Appendix 1</a>, <a href="./appendices#CD005590-sec-0096">Appendix 2</a>, <a href="./appendices#CD005590-sec-0097">Appendix 3</a>. </p> </section> <section id="CD005590-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We inspected the references of all identified studies for more trials.</p> </section> </section> <section id="CD005590-sec-0040"> <h3 class="title" id="CD005590-sec-0040">Data collection and analysis</h3> <section id="CD005590-sec-0041"> <h4 class="title">Selection of studies</h4> <p>For the original 2007 review, HG performed the search and inspected the abstracts of each reference identified. AS performed the search and inspection of abstracts for the review update. Where relevant articles were identified, the full article was obtained and inspected independently by HG and MP (in the original review) and AS and MP in the updated review. We resolved disagreements by discussion. </p> </section> <section id="CD005590-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Data from the included trials were independently extracted into a data extraction sheet by HG and MP in the original review and by AS and MP in the updated review. Differences in the data extraction were resolved by discussion with a third review author (LV or LL). Any missing information was requested from the authors. Outcomes were extracted preferentially by intention to treat, including all the individuals randomised in the outcome assessments. </p> <p>We extracted data on trial characteristics, including time, location and methods of PCP diagnosis, risk of bias (as specified below), interventions, the duration of follow‐up, and outcomes as specified above. </p> </section> <section id="CD005590-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Assessment of risk of bias in each study was performed independently by two authors (HG and MP in the original review and AS and MP in the update). An individual component approach to quality assessment was undertaken using the following variables: selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data) and reporting bias (selective reporting). The grading of the specific risks of bias was expressed as ‘Low risk’, ‘High risk’ or ‘Unclear risk’ of bias using the criteria suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005590-bbs2-0052" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Cochrane Handbook</a> and <a href="#CD005590-tbl-0002">Table 1</a>). </p> <div class="table" id="CD005590-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study quality assessment criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central randomisation in a multi‐center trial or randomisation in pharmacy in a single centre trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No description of methods used for allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any method resulting in a truly random sequence (computer‐generated list, coin tossing, other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No description of methods used for allocation generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of case record numbers, patient identification or admission numbers</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐numbered or coded identical containers administered serially to patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not allocation concealment A or C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of case record numbers, patient identification or admission numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not allocation generation A or C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomisation based on patient's room number</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sequentially numbered, sealed, opaque envelopes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open randomisation lists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computer file accessed only after patient's recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of birth date or admission day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p>The quality of the evidence was graded in the Summary of Findings tables for the main outcomes. </p> </section> <section id="CD005590-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RR) for dichotomous data with 95% confidence intervals (CI). The number needed to treat for an additional beneficial outcome was calculated as 1/(CER ‐ RR*CER), where CER is the control event rate. </p> </section> <section id="CD005590-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>Whenever trials recruited patients more than once for different episodes of immune suppression (for example neutropenia), we attempted to include each patient only once, preferably in the first randomisation. </p> </section> <section id="CD005590-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the first or corresponding author of each included trial for information regarding unpublished trials or supplementary information on their own trial. </p> </section> <section id="CD005590-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>The percentage of variation between the results of trials which could not be ascribed to sampling variation was assessed using the I<sup>2</sup> statistic, and the statistical significance of the heterogeneity was assessed using a Chi<sup>2</sup> test of heterogeneity. </p> </section> <section id="CD005590-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots for PCP infections (SE of log (RR) plotted against RR) were visually examined in order to estimate potential selection bias (publication or other). </p> </section> <section id="CD005590-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We pooled trials comparing:</p> <p> <ul id="CD005590-list-0008"> <li> <p>an antibiotic effective against Pneumocystis versus no treatment or placebo;</p> </li> <li> <p>an antibiotic effective against Pneumocystis versus antibiotic(s) with no activity against Pneumocystis; </p> </li> <li> <p>the same antibiotic effective against PCP given in a different daily or weekly schedule.</p> </li> </ul> </p> <p>For PCP‐related outcomes we also pooled the first two comparisons, thus assessing the overall efficacy of anti‐Pneumocystis prophylaxis. Where possible, we abstracted data by intention‐to‐treat analysis for all randomised patients. We used the random‐effects model throughout the review. </p> </section> <section id="CD005590-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In this update we planned the following subgroup analyses for the primary outcome in order to explore heterogeneity. </p> <p> <ul id="CD005590-list-0009"> <li> <p>Underlying patient conditions: solid organ transplant recipients or other patients.</p> </li> <li> <p>Adults and children.</p> </li> </ul> </p> <p>Too few trials were identified to permit other subgroup analyses that were planned in the original review (type of anti‐Pneumocystis antibiotic and incidence of PCP infections in study). </p> </section> <section id="CD005590-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the effect of study quality on outcomes we planned sensitivity analyses for allocation concealment. This was based on previous evidence showing overestimation of effects with inadequate or unclear allocation concealment (<a href="./references#CD005590-bbs2-0067" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD005590-bbs2-0082" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>). However, too few trials were included in the different comparisons to allow sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005590-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005590-sec-0052"></div> <section id="CD005590-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD005590-sec-0054"> <h4 class="title">Results of the search</h4> <p>The search yielded over 1000 references, most of them not relevant for this review. Forty‐seven studies were considered for the review, of which 13 were included: 11 were included in the original review and two were added in the current update (<a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>). One study found in the trial registry search is ongoing (<a href="./references#CD005590-bbs2-0048" title="The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases. Ongoing studyAugust 2012. ">Fengchun Zhang</a>). </p> </section> <section id="CD005590-sec-0055"> <h4 class="title">Included studies</h4> <p>A total of 1412 patients were randomised of which 520 were children, in five studies. Two trials (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>) evaluated neutropenic episodes (allowing the recruitment of patients more than once), while all other trials included patients only once. The studies were performed between the years 1974 and 2008. One trial that did not specify recruitment dates was published in 1999 (<a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>). The trial characteristics are described in the <a href="./references#CD005590-sec-0106" title="">Characteristics of included studies</a> table. </p> <section id="CD005590-sec-0056"> <h5 class="title">Comparisons</h5> <p>The 13 trials included 14 comparisons. Seven trials compared oral (TMP/SMX) prophylaxis given daily versus placebo or no intervention (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>; <a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>; <a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>; <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>). Two of these included three arms: <a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a> compared TMP/SMX given daily, TMP/SMX given thrice weekly and no prophylaxis; and <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a> compared oral TMP/SMX given daily, quinolones and no prophylaxis. Three trials compared oral TMP/SMX given daily versus quinolones (that have no known anti‐PCP activity) (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>; <a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>). </p> <p>Two trials compared TMP/SMX given daily versus TMP/SMX given thrice weekly, both orally (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>; <a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>). One trial compared oral TMP/SMX given daily versus oral sulfadoxine/pyrimethamine given once a week (<a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>); and one trial compared oral TMP/SMX versus oral atovaquone, both drugs given daily for the first five days of the trial and thrice weekly thereafter (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>). In one trial another antibiotic (colistin) was administrated with TMP/SMX (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>). </p> </section> <section id="CD005590-sec-0057"> <h5 class="title">Underlying immunosuppression</h5> <p>The four trials recruiting children included only children with ALL (<a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>; <a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>). The trials in adults included mainly cancer patients: acute myelocytic leukemia (AML) or ALL (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>; <a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>), multiple myeloma (<a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>), and autologous stem cell transplantation for hematologic and solid cancer (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>). Four adult trials included solid organ transplant recipients: heart (<a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>), renal (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>; <a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>), and liver transplantation (<a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>). </p> <p>All patients were given chemotherapy or anti‐rejection treatment, including corticosteroids in eight trials. None of the trials included patients treated with corticosteroids alone as the underlying risk factor for PCP. </p> </section> <section id="CD005590-sec-0058"> <h5 class="title">Timing of PCP prophylaxis administration</h5> <p>Among hematological cancer patients, prophylaxis was initiated on the first day of induction chemotherapy in three trials (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>; <a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>; <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>), immediately following diagnosis in one trial (<a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>), with neutropenia onset in one trial (<a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>), and variously during anticancer treatment in three trials (<a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>). Prophylaxis was continued until resolution of neutropenia, development of adverse effects, throughout chemotherapy, until relapse, or up to three years of follow‐up (<a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>). In one trial including bone marrow transplant patients (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>) prophylaxis was administered between days ‐1 to ‐5 and from neutropenia resolution (&gt; 100/mm<sup>3</sup>) to day +100. </p> <p>Among solid organ transplant recipients, prophylaxis was initiated in the first week after transplantation and continued for four months (<a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>), six months (<a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>), or up to one year or until graft failure was recorded (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>). </p> </section> <section id="CD005590-sec-0059"> <h5 class="title">Outcomes assessed</h5> <p>All trials except one reported on PCP infections, and in one PCP information was completed by contacting the author (<a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>). Three trials described the occurrence of PCP following prophylaxis discontinuation because of adverse events (<a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>) or after the trial ended (<a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>); these were not included in the overall outcome assessment. Seven trials reported overall mortality and 10 reported on PCP‐related mortality. Thirteen trials reported any infection other than PCP, five of which reported on infection episodes. Neutropenia duration was reported in five trials and four reported bacterial resistance development (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>; <a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>; <a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>). </p> </section> <section id="CD005590-sec-0060"> <h5 class="title">Methods for PCP surveillance and diagnosis</h5> <p>Active surveillance for PCP was conducted in two trials, using monoclonal antibodies in sputum (<a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>) or transthoracic percutaneous needle aspiration of lung parenchyma when diffuse alveolar disease was encountered on chest x‐ray (<a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>). Routine follow‐up chest x‐rays were performed in three trials (<a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>; <a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>). </p> <p>In all trials PCP infections were defined as a clinical disease, not only by microbiological detection. Six trials defined diagnosis of PCP by staining or monoclonal antibodies from a tissue (bronchoalveolar lavage or autopsy). Seven studies did not describe the methods used for the diagnosis of PCP. </p> </section> </section> <section id="CD005590-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Thirty‐four studies were excluded (<a href="./references#CD005590-sec-0107" title="">Characteristics of excluded studies</a>). Seventeen were observational studies, four were reviews, and one study was a computer‐based simulation (<a href="./references#CD005590-bbs2-0017" title="ChungJB , ArmstrongK , SchwartzJS , AlbertD . Cost‐effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis and Rheumatism2000;43(8):1841‐8. ">Chung 2000</a>). We excluded five trials in HIV patients, a RCT that assessed treatment for PCP rather than prophylaxis (<a href="./references#CD005590-bbs2-0046" title="YoungRC , DeVitaVTJr . Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine‐sulfadiazine. National Cancer Institute Monograph1976;43:193‐200. ">Young 1976</a>), one trial that did not use bacteriologic methods to define PCP infection (<a href="./references#CD005590-bbs2-0037" title="RossiMR , BanfiP , CappuccilliM , ConterV , dePoliD , PiacentiniG , et al. Prospective randomized comparison of two prophylactic regimens with trimethoprim‐sulfamethoxazole in leukemic children: a two year study. European Journal of Cancer &amp; Clinical Oncology1987;23(11):1679‐82. ">Rossi 1987</a>), and one trial was never published and data were lost (<a href="./references#CD005590-bbs2-0036" title="PedagogosE , NichollsK , WilsonJ , WaikerR , BeckerG . Comparison of oral trimethoprim/sulfamethoxazole (TMP‐SMX) and inhaled pentamidine (P) for prevention of pneumocystis pneumonia (PCP) after renal transplantation. The Transplantation Society of Australia and New Zealand1994. ">Pedagogos 1994</a>). Finally, we excluded three RCTs that did not assess PCP as an outcome: <a href="./references#CD005590-bbs2-0015" title="AricoM , MolinariE , BacchellaL , DeAmiciM , RaiteriE , BurgioGR . Prospective randomized comparison of toxicity of two prophylactic regimens of cotrimoxazole in leukemic children. Pediatric Hematology and Oncology1992;9(1):35‐40. ">Arico 1992</a> evaluated toxicity only, <a href="./references#CD005590-bbs2-0035" title="OkenMM , PomeroyC , WeisdorfD , BennettJM . Prophylactic antibiotics for the prevention of early infection in multiple myeloma. American Journal of Medicine1996;100(6):624‐8. ">Oken 1996</a> evaluated bacterial infections with no specific data on PCP, and <a href="./references#CD005590-bbs2-0041" title="StegemanCA , TervaertJW , deJongPE , KallenbergCG . Trimethoprim‐sulfamethoxazole (co‐trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co‐Trimoxazole Wegener Study Group. The New England Journal of Medicine1996;335(1):16‐20. ">Stegeman 1996</a> evaluated the effect of TMP/SMX on relapses in Wegener's granulomatosis. </p> </section> </section> <section id="CD005590-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in the included studies is summarized overall in <a href="#CD005590-fig-0001">Figure 1</a> and per study in <a href="#CD005590-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD005590-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005590-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005590-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005590-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005590-sec-0063"> <h4 class="title">Allocation</h4> <p>Random generation of recruitment sequence was described in three trials that were classified as having low risk of bias (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>). One trial that compared once versus thrice weekly TMP/SMX prophylaxis used birth dates for randomisation (<a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>) and was classified at high risk of bias. All the other studies did not describe the methods used for generation of randomisation, and hence were classified as having an unclear risk. </p> <p>Allocation concealment was classified as low risk in four trials (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>; <a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>), high risk in the trial using birth dates (<a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>), and was not reported in all other trials. </p> </section> <section id="CD005590-sec-0064"> <h4 class="title">Blinding</h4> <p>Five trials used double blinding (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>; <a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>; <a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>), while all others were open‐label trials. </p> </section> <section id="CD005590-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>All randomised patients were included for assessment of the primary outcome in three trials that were classified as low‐risk (<a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>; <a href="./references#CD005590-bbs2-0006" title="HughesWT , KuhnS , ChaudharyS , FeldmanS , VerzosaM , AurRJ , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1977;297(26):1419‐26. ">Hughes 1977</a>; <a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>). Seven trials described the reasons for dropouts and non‐evaluability and were similarly considered at low risk for attrition bias. The remaining three trials were classified as high risk (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>; <a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>; <a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>). </p> </section> <section id="CD005590-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Based on the comparison between methods and results (lacking protocols, trial registry data for all trials), all but one study quantitatively reported the designated outcomes. In one study outcomes were not defined in the methods (<a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>). </p> </section> <section id="CD005590-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>All trials but three (<a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>; <a href="./references#CD005590-bbs2-0011" title="vanEysJ , BerryDM , CristW , DoeringEJ , FernbachDJ , PullenJ , et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer1987;59(1):19‐23. ">Van Eys 1987</a>; <a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>) reported that informed consent was obtained from patients. Eight trials reported ethics committee approval. </p> </section> </section> <section id="CD005590-sec-0068"> <h3 class="title" id="CD005590-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD005590-tbl-0001"><b>Summary of findings for the main comparison</b> TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</a> </p> <section id="CD005590-sec-0069"> <h4 class="title">Prophylaxis with TMP/SMX versus no intervention, placebo or a non‐antiPCP antibiotic</h4> <section id="CD005590-sec-0070"> <h5 class="title">Documented PCP infection</h5> <p>Ten trials, including 1000 patients, were included in this comparison. No events occurred in four trials. Only one case of PCP occurred in the prophylaxis arms. There was a significant reduction in the occurrence of PCP infections in the TMP/SMX prophylaxis group compared to the other groups, RR of 0.15 (95% CI 0.04 to 0.62) (<a href="./references#CD005590-fig-0003" title="">Analysis 1.1</a>). Minor heterogeneity was present within this comparison (I<sup>2</sup> = 27%, P = 0.23). The number of patients needed to treat to prevent one episode of PCP was 19 patients (95% CI 17 to 42) with a control event rate (CER) of 31/497 (6.2%). The funnel plot demonstrated a similar SE for trials with different effects, with no small study effect. The quality of the evidence for PCP prevention was graded as moderate, being downgraded only for possible risk of bias related to unknown randomisation methods for most trials and lack of blinding in half of the trials (<a href="./full#CD005590-tbl-0001">summary of findings Table for the main comparison</a>). In four trials no events occurred, in both arms. </p> <p>Seven trials, including 707 patients, compared daily administered TMP/SMX prophylaxis versus no intervention or placebo. Prophylaxis resulted in a decrease in the occurrence of PCP infections, RR of 0.17 (95% CI 0.03 to 1,0). Total events were 26 out of 335 in the no treatment or placebo group compared to 1 out of 372 in the TMP/SMX group. Four trials compared TMP/SMX prophylaxis versus a non‐antiPCP antibiotic (quinolones). One of the trials (<a href="./references#CD005590-bbs2-0012" title="VesoleDH , OkenMM , HecklerC , GreippPR , KatzMS , JacobusS , MorrowGR , on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia2012;26:2517–20. ">Vesole 2012</a>) was a three armed trial and was already included in the TMX/SMX versus no intervention analysis, and was thus excluded from this category of the meta‐analysis. In the three trials that were included in the analysis (total of 293 patients) prophylaxis with TMP/SMX reduced PCP but without statistical significance (RR 0.09, 95% CI 0.01 to 1.57). All events (5/162 in the quinolone group) occurred in a single trial involving renal transplant recipients (<a href="./references#CD005590-bbs2-0005" title="HibberdPL , Tolkoff‐RubinNE , DoranM , DelvecchioA , CosimiAB , DelmonicoFL , et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online Journal of Current Clinical Trials1992; Vol. Doc No 15. ">Hibberd 1992</a>). </p> <p>For the planned subgroup of solid organ transplant recipients (only adults included) the RR was 0.09 (95% CI 0.02 to 0.48) (<a href="./references#CD005590-fig-0004" title="">Analysis 1.2</a>), while among hematological cancer adults and children the RR was 0.28 (95% CI 0.02 to 4.57) (<a href="./references#CD005590-fig-0005" title="">Analysis 1.3</a>). Too few studies were available to perform subgroup analysis according to different rates of PCP infection in the studies, and no trials assessed antibiotics other than TMP/SMX. The effects among adults (RR 0.20, 95% CI 0.03 to 1.37, CER 4.0%) and children with ALL (RR 0.09, 95% CI 0.01 to 1.15, CER 10.6%) were similar, not reaching statistical significance in either subgroup (<a href="./references#CD005590-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD005590-sec-0071"> <h5 class="title">All cause mortality</h5> <p>Six trials, including 652 patients, reported this outcome (<a href="./references#CD005590-fig-0007" title="">Analysis 1.5</a>). Four trials compared TMP/SMX to placebo, RR of 0.58 (95% CI 0.17 to 2). This result was graded as low quality due to high imprecision. Two trials compared TMP/SMX versus quinolones (RR 0.49, 95% CI 0.02 to 10.73) and the pooled RR for all trials examining anti‐PCP prophylaxis was 0.71 (95% CI 0.28 to 1.80), without heterogeneity. </p> </section> <section id="CD005590-sec-0072"> <h5 class="title">PCP‐related mortality</h5> <p>Nine trials, including 886 patients, reported on PCP‐related mortality. Overall, TMP/SMX prophylaxis reduced PCP‐related mortality, RR of 0.17 (95% CI 0.03 to 0.94) (<a href="./references#CD005590-fig-0008" title="">Analysis 1.6</a>). The quality of the evidence was graded as low due to possible risk of bias, as above, and imprecision. </p> <p>Six trials, including 593 patients, compared TMP/SMX versus no intervention or placebo and three studies, including 293 patients, compared TMP/SMX versus quinolones. In both comparisons the PCP rates were lower with TMP/SMX but without statistical significance due to small sample sizes and low event rates. </p> </section> <section id="CD005590-sec-0073"> <h5 class="title">Any infection other than PCP</h5> <p>Three studies, including 299 patients, comparing TMP/SMX prophylaxis versus no intervention or placebo reported this outcome (<a href="./references#CD005590-fig-0010" title="">Analysis 1.8</a>). There was no statistically significant difference between the groups, RR of 0.90 (95% CI 0.74 to 1.1). Four studies that compared TMP/SMX prophylaxis versus quinolones, including 431 patients, reported this outcome. Significantly more infections other than PCP occurred in the TMP/SMX arm compared to the quinolones arm, RR of 1.49 (95% CI 1.14 to 1.96). </p> </section> <section id="CD005590-sec-0074"> <h5 class="title">Bacterial infections</h5> <p>Four studies (399 patients) comparing TMP/SMX versus no treatment reported on the incidence of bacterial infections (<a href="./references#CD005590-fig-0009" title="">Analysis 1.7</a>). There was a significant decrease in the rate of bacterial infections in the prophylaxis group, RR.of 0.44 (95% CI 0.21 to 0.9). </p> <p>Four studies (431 patients) comparing TMP/SMX versus quinolones reported this outcome. There were more bacterial infections in the TMP/SMX group, RR of 2.04 (95% CI 0.8 to 5.23). </p> </section> <section id="CD005590-sec-0075"> <h5 class="title">Resistance development</h5> <p>Three studies comparing TMP/SMX versus no treatment reported on resistance to TMP/SMX for bacterial infections developing during the trial. Resistance rates were 62% versus 18% of isolates in one trial (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>) and 26% versus 0 patients in the other (<a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a>). The third trial reported that all patients in both groups acquired one or more trimetoprim‐resistant organisms throughout the study period (<a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a>). </p> <p>One trial comparing TMP/SMX to ofloxacin (<a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>) reported that colonisation with isolates resistant to TMP/SMX increased from 24% of isolates to 66% during treatment, whereas resistance to ofloxacin remained null throughout the trial. </p> </section> <section id="CD005590-sec-0076"> <h5 class="title">Adverse events</h5> <p>Four trials comparing TMP/SMX prophylaxis versus no intervention or placebo reported on the occurrence of any type of adverse effects (<a href="./references#CD005590-fig-0011" title="">Analysis 1.9</a>). These studies included 470 patients. There was no significant difference in the adverse effects rate between the two groups, RR of 1.01 (95% CI 0.82 to 1.24). Three trials reported adverse events that required discontinuation of the treatment (<a href="./references#CD005590-fig-0012" title="">Analysis 1.10</a>) and five trials reported on severe adverse events requiring permanent discontinuation, as defined in our protocol (<a href="./references#CD005590-fig-0013" title="">Analysis 1.11</a>). No severe adverse events or adverse events requiring treatment discontinuation were reported with TMP/SMX, while several events were reported with placebo or no treatment. It should be noted that adverse events were caused by underlying conditions or chemotherapy as well as by TMP/SMX. The quality of the evidence for this outcome was rated as moderate due to imprecision. </p> <p>Two trials comparing TMP/SMX prophylaxis versus quinolones reported on any adverse effects (<a href="./references#CD005590-fig-0011" title="">Analysis 1.9</a>). These trials included 191 patients. There were significantly more adverse effects in the TMP/SMX group, RR of 4.66 (95% CI 2.55 to 8.53). Adverse events requiring temporary treatment discontinuation (<a href="./references#CD005590-fig-0012" title="">Analysis 1.10</a>) and severe adverse events requiring permanent discontinuation (<a href="./references#CD005590-fig-0013" title="">Analysis 1.11</a>) were also more common with TMP/SMX. Severe adverse events, which included leukopenia and thrombocytopenia, resolved following treatment withdrawal. </p> <p>When looking for the more common adverse events associated with TMP/SMX, rash was reported in four trials comparing TMP/SMX prophylaxis versus no intervention or placebo (392 patients) and in two trials comparing TMP/SMX versus quinolones (191 patients). The RRs were 0.38 (95% CI 0.09 to 1.52) and 3.94 (95% CI 1.35 to 11.46), respectively (<a href="./references#CD005590-fig-0014" title="">Analysis 1.12</a>). Three studies that compared TMP/SMX prophylaxis versus no intervention or placebo reported the rates of leukopenia. Only one study comparing TMP/SMX versus quinolones reported this outcome. The RRs were 1.45 (95% CI 0.84 to 2.5) and 1.96 (95% CI 0.18 to 20.97), respectively (<a href="./references#CD005590-fig-0015" title="">Analysis 1.13</a>). Trials reporting on neutropenia duration could not be combined. The mean number of days with neutropenia were reported in one trial involving adults with acute myeloid leukemia (AML) or ALL (<a href="./references#CD005590-bbs2-0008" title="LiangRH , YungRW , ChanTK , ChauPY , LamWK , SoSY , et al. Ofloxacin versus co‐trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy1990;34(2):215‐8. ">Liang 1990</a>): 15.8 ± 1.1 days for TMP/SMX versus 14.9 ± 1.1 days for ofloxacin. The median number of days with neutropenia was reported in two trials. <a href="./references#CD005590-bbs2-0013" title="WardTT , ThomasRG , FyeCL , ArbeitR , ColtmanCAJr , CraigW , et al. Trimethoprim‐sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double‐blind, placebo‐controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases1993;17(3):323‐32. ">Ward 1993</a> (AML and ALL adults) reported medians of 26 days with TMP/SMX versus 30 days with the placebo groups; <a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a> (AML and ALL adults) reported 20 days in the TMP/SMX group versus 10 days in the ciprofloxacin group versus 16 days in the ofloxacin group. The total number of days with neutropenia were reported in one trial in renal transplantation patients (<a href="./references#CD005590-bbs2-0003" title="FoxBC , SollingerHW , BelzerFO , MakiDG . A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. American Journal of Medicine1990;89(3):255‐74. MakiDG , FoxBC , KuntzJ , SollongerHW , BelzerOB . A prospective, randomised, double‐blind study of thrimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim‐sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine1992;119(1):11‐24. ">Fox 1990</a>): 35 days for the TMP/SMX group and 23 days for the placebo group. <a href="./references#CD005590-bbs2-0004" title="GoorinAM , HersheyBJ , LevinMJ , SiberGR , GelberRD , FlynnK , et al. Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease1985;4(3):265‐9. ">Goorin 1985</a> (ALL children) reported on the mean nadir of the neutrophil count, which was 172 (113 to 262) in the TMP/SMX group versus 172 (240 to 343) in the placebo group. </p> </section> </section> <section id="CD005590-sec-0077"> <h4 class="title">Daily versus thrice weekly TMP/SMX prophylaxis</h4> <section id="CD005590-sec-0078"> <h5 class="title">Documented PCP infections and PCP‐related mortality</h5> <p>Two studies, including 205 patients, were included in this comparison (<a href="./references#CD005590-fig-0016" title="">Analysis 2.1</a>). No events occurred in either study arm. The trials included patients with acute leukemia (<a href="./references#CD005590-bbs2-0007" title="HughesWT , RiveraGK , SchellMJ , ThorntonD , LottL . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine1987;316(26):1627‐32. ">Hughes 1987</a>) and cardiac transplantation (<a href="./references#CD005590-bbs2-0009" title="OlsenSL , RenlundDG , O'ConnellJB , TaylorDO , LassetterJE , EastburnTE , et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation1993;56(2):359‐62. ">Olsen 1993</a>). </p> </section> <section id="CD005590-sec-0079"> <h5 class="title">Any infection other than PCP</h5> <p>This outcome was reported in one study (<a href="./references#CD005590-fig-0023" title="">Analysis 2.8</a>) including 167 patients. There was no difference between daily administered TMP/SMX versus thrice weekly TMP/SMX (RR 1.06, 95% CI 0.58 to 1.93). </p> </section> <section id="CD005590-sec-0080"> <h5 class="title">Bacterial infections</h5> <p>One study, including 167 patients, reported this outcome (<a href="./references#CD005590-fig-0024" title="">Analysis 2.9</a>). There was no significant difference in the occurrence of bacterial infections (RR 1.35, 95% CI 0.66 to 2.78). </p> <p>All cause mortality, resistance development, and adverse effects requiring discontinuation were not reported in this subgroup of studies. </p> </section> <section id="CD005590-sec-0081"> <h5 class="title">Adverse events</h5> <p>The two trials, including 207 patients, reported on adverse events. There were no significant differences in rates of any adverse event or adverse events requiring discontinuation, and no severe adverse events were reported (<a href="./references#CD005590-fig-0018" title="">Analysis 2.3</a>, <a href="./references#CD005590-fig-0019" title="">Analysis 2.4</a>, <a href="./references#CD005590-fig-0020" title="">Analysis 2.5</a>). Rash occurred less frequently with daily TMP/SMX administration but this was not significant (RR 0.51, 95% CI 0.23 to 1.16) (<a href="./references#CD005590-fig-0021" title="">Analysis 2.6</a>). Leukopenia was reported in only one study (<a href="./references#CD005590-fig-0022" title="">Analysis 2.7</a>), including 167 patients, and occurred more frequently with daily TMP/SMX but the difference was not statistically significant (RR 2.78, 95% CI 0.60 to 13.01). </p> </section> </section> <section id="CD005590-sec-0082"> <h4 class="title">Other comparisons</h4> <p>Two trials fulfilling the inclusion criteria were not included in the previous comparisons. One trial compared daily TMP/SMX versus sulfadoxine/pyrimethamine given once a week (<a href="./references#CD005590-bbs2-0010" title="Torre‐CisnerosJ , De laMataM , PozoJC , SerranoP , BricenoJ , SolorzanoG , et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low‐dose trimethoprim‐sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease1999;29(4):771‐4. ">Torre‐Cisneros 1999</a>), including 125 patients following liver transplantation. There were two documented PCP infections out of 60 patients in the TMP/SMX group, versus no infections in the sulfadoxine/pyrimethamine group. Both cases of PCP occurred after TMP/SMX prophylaxis was discontinued because of adverse effects. All cause mortality rates were 13/60 and 12/60 respectively. None of the deaths were due to PCP infection. Infections other than PCP were detected among 35/60 patients in the TMP/SMX group and among 39/60 in the sulfadoxine/pyrimethamine group. Any adverse event occurred in 11/60 versus 10/60, respectively; three required discontinuation in the TMP/SMX group and four in the sulfadoxine/pyrimethamine group. Leukopenia developed in six patients in the TMP/SMX group versus four patients in the sulfadoxine/pyrimethamine group. </p> <p>One trial including 39 patients after autologous peripheral blood stem cell (PBSC) transplantation for hematologic and solid malignancies compared TMP/SMX versus atovaquone (<a href="./references#CD005590-bbs2-0002" title="ColbyC , McAfeeS , SacksteinR , FinkelsteinD , FishmanJ , SpitzerT . A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation1999;24(8):897‐902. ">Colby 1999</a>). Both drugs were given daily for five days before transplantation (until day ‐1) and then thrice weekly. No cases of PCP were recorded in either group. All cause mortality was not reported and no infection other than PCP developed. There were eight adverse events recorded in the TMP/SMX group (8/18, two cases of leukopenia, all requiring discontinuation of treatment) versus none in the atovaquone group. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005590-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005590-sec-0083"></div> <section id="CD005590-sec-0084"> <h3 class="title" id="CD005590-sec-0084">Summary of main results</h3> <p>TMP/SMX was the antibiotic most commonly assessed for prevention of PCP infections, thus the review addressed mainly the efficacy of TMP/SMX. Overall, TMP/SMX was highly effective in preventing PCP infections, showing a 85% reduction in the incidence of PCP infections (RR 0.15, 95% CI 0.04 to 0.62) without significant heterogeneity. All cause mortality was not significantly reduced with prophylaxis (RR 0.71, 95% CI 0.28 to 1.8) but since there were fewer PCP infections, PCP‐related mortality was reduced by 83% (RR 0.17, 95% CI 0.03 to 0.94). </p> <p>There was an advantage for TMP/SMX prophylaxis over no treatment in preventing bacterial infections (RR 0.44, 95% CI 0.21 to 0.90) in the populations assessed in the included trials. Quinolone treatment was significantly better than TMP/SMX in preventing any infection other than PCP (RR 1.90, 95% CI 1.14 to 1.96) but not specifically bacterial infections (RR 2.04, 95% CI 0.80 to 5.23). </p> <p>No difference was encountered between once versus thrice weekly prophylaxis with TMP/SMX for all outcomes described above, but few trials were included in this comparison. According to these results, there is no superiority for daily prophylaxis over thrice weekly prophylaxis with TMP/SMX. </p> <p>For adverse effects, a meta‐analysis of four trials showed no difference between TMP/SMX and no prophylaxis (RR 1.01, 95% CI 0.82 to 1.24), while two trials comparing TMP/SMX to quinolone prophylaxis showed more adverse effects with TMP/SMX (RR 4.66, 95% CI 2.55 to 8.53). Among trials comparing TMP/SMX to placebo or no treatment, no severe adverse events were observed with TMP/SMX. Overall, combining all TMP/SMX treatment arms included in this systematic review, severe adverse events requiring permanent discontinuation, including leukopenia, thrombocytopenia or severe dermatological reactions, occurred in 3.1% of adults (six trials) and 0% among children (five trials). The adverse effect most important to the patient population assessed in these trials (hematological cancer patients and organ transplant recipients) is leukopenia. There was a greater risk of leukopenia in the TMP/SMX group when compared to placebo or no intervention (RR 1.45, 95% CI 0.84 to 2.50) and when comparing with quinolones (RR 1.96, 95% CI 0.18 to 20.97). However, only four trials were included in these comparisons. Longer duration of neutropenia was reported with TMP/SMX treatment compared to quinolone treatment but, again, only the minority of trials reported this outcome and the data could not be combined. </p> </section> <section id="CD005590-sec-0085"> <h3 class="title" id="CD005590-sec-0085">Overall completeness and applicability of evidence</h3> <p>The trials included in this review assessed patients with hematological malignancies, bone marrow transplant patients (five trials with children, three trials with adults) or solid organ transplant recipients (four trials). The overall rate of PCP infections in these studies was 6.2%, and for this control event rate the number needed to treat in order to prevent one PCP infection is 19 patients (95% CI 17 to 42). Our results apply to populations with a similar risk of PCP infections. </p> <p>Among most cancer patients rates are usually below 1% (<a href="./references#CD005590-bbs2-0080" title="RouxA , GonzalezF , RouxM , MehradM , MenottiJ , ZaharJR , et al. Groupe de recherche respiratoire en réanimation en onco‐hématologie (Grrr‐OH). Update on pulmonary Pneumocystis jirovecii infection in non‐HIV patients. Médecine et Maladies Infectieuses2014;44(5):185‐98. ">Roux 2014</a>; <a href="./references#CD005590-bbs2-0084" title="SepkowitzKA . Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases2002;34:1098‐107. ">Sepkowitz 2002</a>). Higher rates are observed among patients after allogeneic bone marrow transplantation. Reported rates were 5% to 16% before the use of PCP prophylaxis, declining to 1.5% to 2.5% with the widespread use of TMP/SMX prophylaxis in this population (<a href="./references#CD005590-bbs2-0053" title="DeCastroN , NeuvilleS , SarfatiC , RibaudP , DerouinF , GluckmanE , et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6‐year retrospective study. Bone Marrow Transplantation2005;36(10):879‐83. ">De Castro 2005</a>; <a href="./references#CD005590-bbs2-0077" title="RoblotF , GodetC , LeMoalG , GaroB , Faouzi SoualaM , DaryM , et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV‐negative patients. European Journal of Clinical Microbiology &amp; Infectious Diseases2002;21(7):523‐31. ">Roblot 2002</a>). The risk of PCP in patients with autologous stem cell transplantation is unknown. In a study from France, the incidence of PCP in patients with autologous hematopoietic stem cell transplantation (HSCT) was 0.54% (<a href="./references#CD005590-bbs2-0077" title="RoblotF , GodetC , LeMoalG , GaroB , Faouzi SoualaM , DaryM , et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV‐negative patients. European Journal of Clinical Microbiology &amp; Infectious Diseases2002;21(7):523‐31. ">Roblot 2002</a>). In solid organ transplant patients, without prophylaxis the rate of PCP ranges from 5% to 15%. Among lung and heart‐lung transplant recipients the rates are high, ranging from 10% to 40% without prophylaxis (<a href="./references#CD005590-bbs2-0065" title="MartinSI , FishmanJA , AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. American Journal of Transplantation2013;13 Suppl 4:272‐9. ">Martin 2013</a>; <a href="./references#CD005590-bbs2-0084" title="SepkowitzKA . Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases2002;34:1098‐107. ">Sepkowitz 2002</a>). PCP occurs in 1% to 2% of all patients with rheumatologic disorders, most often, but not always, among those receiving immunosuppressive therapy (<a href="./references#CD005590-bbs2-0038" title="SingerNG , McCuneWJ . Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Current Opinion in Rheumatology1999;11(3):173‐8. ">Singer 1999</a>). Patients with Wegener's granulomatosis, polyarteritis nodosa, and to a lesser degree polymyositis or dermatomyositis are at higher risk, with incidence rates of 8% to 12%, 6.5% and 2.7%, respectively (<a href="./references#CD005590-bbs2-0080" title="RouxA , GonzalezF , RouxM , MehradM , MenottiJ , ZaharJR , et al. Groupe de recherche respiratoire en réanimation en onco‐hématologie (Grrr‐OH). Update on pulmonary Pneumocystis jirovecii infection in non‐HIV patients. Médecine et Maladies Infectieuses2014;44(5):185‐98. ">Roux 2014</a>). While the risk among patients with inflammatory bowel disease is higher than the general population, it is low in absolute terms (about 1/1000), and most patients who are affected receive steroids combined with other immunosuppressive medications (<a href="./references#CD005590-bbs2-0062" title="LongMD , FarrayeFA , OkaforPN , MartinC , SandlerRS , KappelmanMD . Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(5):1018‐24. ">Long 2013</a>; <a href="./references#CD005590-bbs2-0084" title="SepkowitzKA . Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases2002;34:1098‐107. ">Sepkowitz 2002</a>). PCP has been described among other patients who have been administered chronic steroid treatment for autoimmune disease, dermatological diseases, chronic pulmonary disease and hematological malignancy (<a href="./references#CD005590-bbs2-0076" title="RaychaudhuriSP , SiuS . Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases. British Journal of Dermatology1999;141:528‐30. ">Raychaudhuri 1999</a>; <a href="./references#CD005590-bbs2-0045" title="WorthLJ , DooleyMJ , SeymourJF , MileshkinL , SlavinMA , ThurskyKA . An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer2005;92(5):867‐72. ">Worth 2005</a>). In a retrospective analysis from the Mayo Clinic, the median steroid dose was equivalent to 30 mg of prednisone and the median duration of treatment before the development of PCP was 12 weeks (<a href="./references#CD005590-bbs2-0088" title="YaleSH , LimperAH . Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clinics Proceedings1996;71:5‐13. ">Yale 1996</a>). Recently, reports of PCP among patients with rheumatoid arthritis and Crohn's disease who are receiving anti‐TNFalfa antibodies have been described, but the incidence rates are lower than 0.5% (<a href="./references#CD005590-bbs2-0054" title="EllerinT , RubinRH , WeinblattME . Infections and anti‐tumor necrosis factor alpha therapy. Arthritis and Rheumatism2003;48:3013‐22. ">Ellerin 2003</a>; <a href="./references#CD005590-bbs2-0055" title="FDA . Safety update on TNF‐alfa antagonists: infliximab and etanerecept. Food and Drug Administration, Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting, 2001. ">FDA 2001</a>; <a href="./references#CD005590-bbs2-0080" title="RouxA , GonzalezF , RouxM , MehradM , MenottiJ , ZaharJR , et al. Groupe de recherche respiratoire en réanimation en onco‐hématologie (Grrr‐OH). Update on pulmonary Pneumocystis jirovecii infection in non‐HIV patients. Médecine et Maladies Infectieuses2014;44(5):185‐98. ">Roux 2014</a>). Outbreaks with suspected airborne person‐to‐person transmission have been documented in high‐risk units, increasing the risk for individuals exposed above their baseline risk (<a href="./references#CD005590-bbs2-0050" title="ChapmanJR , MarriottDJ , ChenSC , MacDonaldPS . Post‐transplant Pneumocystis jirovecii pneumonia‐‐a re‐emerged public health problem?. Kidney International2013;84(2):240‐3. ">Chapman 2013</a>; <a href="./references#CD005590-bbs2-0069" title="NankivellBJ , FiracativeC , KableK , ChenSC , MeyerW . Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clinical Infectious Diseases2013;57(7):1058‐9. ">Nankivell 2013</a>; <a href="./references#CD005590-bbs2-0079" title="RostvedAA , SassiM , KurtzhalsJA , SorensenSS , RasmussenA , RossC , et al. Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation2013;96:834‐42. ">Rostved 2013</a>; <a href="./references#CD005590-bbs2-0089" title="YazakiH , GotoN , UchidaK , KobayashiT , GatanagaH , OkaS . Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation2009;88:380‐5. ">Yazaki 2009</a>). </p> <p>Our original intention was to search for evidence on PCP prophylaxis for non‐HIV patients chronically treated with steroids for collagen vascular diseases, chronic lung disease, inflammatory bowel disease, etc. We did not find published studies addressing this patient population. </p> </section> <section id="CD005590-sec-0086"> <h3 class="title" id="CD005590-sec-0086">Quality of the evidence</h3> <p>Most of the studies used for this review are old (eight out of 13 were published from 1977 to 1990) and included a small number of patients. One trial (<a href="./references#CD005590-bbs2-0001" title="ArningM , WolfHH , AulC , HeyllA , ScharfRE , ScheiderW . Infection prophylaxis in neutropenic patients with acute leukaemia‐‐a randomized, comparative study with ofloxacin, ciprofloxacin and co‐trimoxazole/colistin. Journal of Antimicrobial Chemotherapy1990;26 Suppl D:137‐42. ">Arning 1990</a>) included patients more than once in the trial, for different neutropenic episodes, and we did not have the data to adjust for clustering. The 95% CI for this trial might be artificially narrow and the weight assigned to it in the meta‐analysis artificially high. The confidence in the main results was low to moderate (<a href="./full#CD005590-tbl-0001">summary of findings Table for the main comparison</a>) due to unclear risk of bias in most trials and imprecision of results, mainly for all cause mortality, which was reported in a selection of the trials only. </p> <p>These trials could not assess the effect of TMP/SMX prophylaxis on development of <i>Pneumocystis jirovecii</i> resistance to TMP/SMX or clinical failure with TMP/SMX treatment following TMP/SMX prophylaxis since only one infection occurred in the prophylaxis group. Among HIV patients, a previous systematic review showed that TMP/SMX prophylaxis was significantly associated with mutations in the dihydropteroate synthase (DHPS) enzyme of <i>Pneumocystis spp</i>. (<a href="./references#CD005590-bbs2-0085" title="SteinCR , PooleC , KazanjianP , MeshnickSR . Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerging Infectious Diseases2004;10:1760‐5. ">Stein 2004</a>). Clinically, the relationship between DHPS mutations and failure of TMP/SMX treatment is unclear; studies show results that are highly heterogeneous, which precludes an appraisal of the effect of TMP/SMX prophylaxis on clinical resistance to treatment of subsequent PCP with TMP/SMX (<a href="./references#CD005590-bbs2-0059" title="HuangL , CrothersK , AtzoriC , BenfieldT , MillerR , RabodonirinaM , Helweg‐LarsenJ . Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerging Infectious Diseases2004;10(10):1721‐8. ">Huang 2004</a>; <a href="./references#CD005590-bbs2-0085" title="SteinCR , PooleC , KazanjianP , MeshnickSR . Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerging Infectious Diseases2004;10:1760‐5. ">Stein 2004</a>). In one study that evaluated 152 episodes of PCP in 144 HIV patients, DHPS mutations were found to be an independent predictor associated with increased death rates. Whether this increased death rate was due to failure of TMP/SMX for PCP treatment is unclear (<a href="./references#CD005590-bbs2-0058" title="Helweg‐LarsenJ , BenfieldTL , Eugen‐OlsenJ , LundgrenJD , LundgrenB . Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS‐associated P. carinii pneumonia. Lancet1999;354(9187):1347‐51. ">Helweg‐Larsen 1999</a>). In a different study, among 97 patients with AIDS and PCP the presence of DHPS mutations was associated with an increased risk for PCP treatment failure (RR 2.1, P = 0.01) (<a href="./references#CD005590-bbs2-0061" title="KazanjianP , ArmstrongW , HosslerPA , BurmanW , RichardsonJ , LeeCH , et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. Journal of Infectious Diseases2000;182:551‐7. ">Kazanjian 2000</a>). In contrast, other studies found no association between the presence of DHPS mutations and mortality or PCP treatment failure (<a href="./references#CD005590-bbs2-0070" title="NavinTR , BeardCB , HuangL , delRioC , LeeS , PieniazekNJ , et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV‐1: a prospective study. Lancet2001;358:545‐9. ">Navin 2001</a>; <a href="./references#CD005590-bbs2-0074" title="RabodonirinaM , VaillantL , TaffeP , NahimanaA , GillibertRP , VanhemsP , et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV‐infected patients with pneumonia. Emerging Infectious Diseases2013;19:21‐8; quiz 186. ">Rabodonirina 2013</a>). </p> </section> <section id="CD005590-sec-0087"> <h3 class="title" id="CD005590-sec-0087">Potential biases in the review process</h3> <p>Data from this review are insufficient to address the overall gain versus detrimental effects associated with TMP/SMX prophylaxis since we limited inclusion to trials that assessed PCP infections. Thus, our comparisons for all cause mortality, infections other than PCP, bacterial infections and adverse events are incomplete. </p> <p>Publication bias is of concern since almost all trials showed absolute PCP protection with TMP/SMX. However, TMP/SMX, available in the US since 1973 and in the UK since 1969, was no longer a patented drug at the time most of these trials were conducted. Most commonly PCP was not the primary outcome, thus intentional bias is unlikely. For these reasons we do not believe that our results are due to publication bias, though some effect cannot be ruled out. </p> <p>A clinical question that is raised when considering TMP/SMX prophylaxis, mainly among cancer patients, is the adjunctive administration of leucovorin (folinic acid) to prevent myelosuppression. It is unclear whether leucovorin can prevent TMP/SMX‐induced neutropenia, and whether it interferes with the efficacy of TMP/SMX. No studies examining this question in non‐HIV patients were found. A randomised controlled trial compared tolerance to prophylaxis with TMP‐SMX versus TMP‐SMX with leucovorin in patients with advanced HIV. There was a non‐significantly lower rate of leucopenia in recipients of leucovorin compared to patients who did not receive leucovorin (rate ratio 0.2, 95% CI 0.0 to 1.7) but there was no difference in discontinuation of the prophylaxis. Clinical efficacy was not addressed in this study (<a href="./references#CD005590-bbs2-0049" title="BozzetteSA , ForthalD , SattlerFR , KemperC , RichmanDD , TillesJG , et al. The tolerance for zidovudine plus thrice weekly or daily trimethoprim‐sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. American Journal of Medicine1995;98:177‐82. ">Bozzette 1995</a>). In a randomised trial evaluating the ability of leucovorin to reduce TMP/SMX‐induced toxicity in the treatment of acute PCP in 92 AIDS patients, a significant reduction in neutropenia was noted in patients receiving leucovorin (23% versus 47%, P = 0.03) (<a href="./references#CD005590-bbs2-0081" title="SafrinS , LeeBL , SandeMA . Adjunctive folinic acid with trimethoprim‐sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. Journal of Infectious Diseases1994;170:912‐7. ">Safrin 1994</a>). However, leucovorin also resulted in a reduction in treatment efficacy (15% versus 0% failures, P = 0.005; 11% versus 0% deaths, P = 0.02 for leucovorin versus placebo). Thus, the overall benefit‐risk of administering leucovorin concomitantly with TMP/SMX for prophylaxis is unclear for HIV patients and there are no data for non‐HIV patients. </p> </section> <section id="CD005590-sec-0088"> <h3 class="title" id="CD005590-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>A Cochrane systematic review assessed TMP/SMX prophylaxis among adults with HIV (<a href="./references#CD005590-bbs2-0057" title="GrimwadeK , SwinglerG . Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003108] ">Grimwade 2005</a>). In three randomised controlled trials comparing TMP/SMX versus placebo or no treatment, no PCP events occurred and mortality was significantly reduced with prophylaxis. In a single trial comparing TMP/SMX with leucovorin versus no treatment among patients with HIV who were not on antiretroviral therapy and were receiving chemotherapy for Kaposi sarcoma, PCP infections were significantly reduced with a RR of 0.31 (95% CI 0.13 to 0.74). In two trials of cotrimoxazole prophylaxis for children with HIV, mortality was significantly reduced with prophylaxis in both trials; in one trial PCP was not reported (<a href="./references#CD005590-bbs2-0066" title="MerminJ , LuleJ , EkwaruJP , MalambaS , DowningR , RansomR , et al. Effect of co‐trimoxazole prophylaxis on morbidity, mortality, CD4‐cell count, and viral load in HIV infection in rural Uganda. Lancet2004;364(9443):1428‐34. ">Mermin 2004</a>) and in the other a single case of PCP occurred in the placebo group (<a href="./references#CD005590-bbs2-0051" title="ChintuC , BhatGJ , WalkerAS , MulengaV , SinyinzaF , LishimpiK , et al. CHAP trial team. Co‐trimoxazole as prophylaxis against opportunistic infections in HIV‐infected Zambian children (CHAP): a double‐blind randomised placebo‐controlled trial. Lancet2004;364(9448):1865‐71. ">Chintu 2004</a>). Thus, among HIV patients TMP/SMX prophylaxis significantly reduces mortality, and PCP infections were not always examined. In our review, TMP/SMX prophylaxis prevented PCP infections and PCP‐related mortality. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005590-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005590-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005590-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 1 Documented PCP infections." data-id="CD005590-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 1 Documented PCP infections. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 2 Documented PCP infections ‐ solid organ transplant subgroup." data-id="CD005590-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 2 Documented PCP infections ‐ solid organ transplant subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 3 Documented PCP infections ‐ hematological cancer subgroup." data-id="CD005590-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 3 Documented PCP infections ‐ hematological cancer subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 4 Documented PCP infections ‐ adults vs. children." data-id="CD005590-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 4 Documented PCP infections ‐ adults vs. children. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 5 All cause mortality." data-id="CD005590-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 5 All cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 6 PCP‐related mortality." data-id="CD005590-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 6 PCP‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 7 Bacterial infections." data-id="CD005590-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 7 Bacterial infections. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 8 Any infections other than PCP." data-id="CD005590-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 8 Any infections other than PCP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 9 Adverse events: any." data-id="CD005590-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 9 Adverse events: any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 10 Adverse events: requiring temporary or permanent treatment discontinuation." data-id="CD005590-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 10 Adverse events: requiring temporary or permanent treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 11 Adverse events: severe adverse events requiring treatment discontinuation." data-id="CD005590-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 11 Adverse events: severe adverse events requiring treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 12 Adverse events: rash." data-id="CD005590-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 12 Adverse events: rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 13 Adverse events: leukopenia." data-id="CD005590-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 TMP/SMX versus placebo, no treatment or non‐PCP drug, Outcome 13 Adverse events: leukopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 1 Documented PCP infections." data-id="CD005590-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 1 Documented PCP infections. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 2 PCP‐related mortality." data-id="CD005590-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 2 PCP‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 3 Adverse events: any." data-id="CD005590-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 3 Adverse events: any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 4 Adverse events: requiring temporary or permanent treatment discontinuation." data-id="CD005590-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 4 Adverse events: requiring temporary or permanent treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 5 Adverse events: severe adverse events requiring treatment discontinuation." data-id="CD005590-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 5 Adverse events: severe adverse events requiring treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 6 Adverse events: rash." data-id="CD005590-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 6 Adverse events: rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 7 Adverse events: leukopenia." data-id="CD005590-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 7 Adverse events: leukopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 8 Any infections other than PCP." data-id="CD005590-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 8 Any infections other than PCP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005590-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/urn:x-wiley:14651858:media:CD005590:CD005590-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_t/tCD005590-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 9 Bacterial infections." data-id="CD005590-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Continuous daily versus thrice weekly TMP‐SMX, Outcome 9 Bacterial infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/media/CDSR/CD005590/image_n/nCD005590-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005590-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients<br/> <b>Settings:</b> <br/> <b>Intervention:</b> TMP/SMX versus placebo, no treatment or non‐PCP drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TMP/SMX versus placebo, no treatment or non‐PCP drug</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Documented PCP infections</b> <br/> Clinical and microbiological criteria<br/> Follow‐up: 1‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1000<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (2 to 39) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (0 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cause mortality ‐ TMP/SMX versus placebo or no treatment</b> <br/> Follow‐up: 2‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.58</b> <br/> (0.17 to 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>461<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (5 to 62) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCP‐related mortality</b> <br/> Clinical only </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (1 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.17</b> <br/> (0.03 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment</b> <br/> Clinical and laboratory criteria and treatment discontinuations </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (1 to 27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> <br/> (0.05 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomisation methods were not described in most trials and only half were blinded.<br/> <sup>2</sup> No serious inconsistency (I<sup>2</sup> = 0%).<br/> <sup>3</sup> Small trials with few events (11 deaths in total), unpowered to examine the effects of prophylaxis on mortality. Pooled effect ranges from no benefit to benefit.<br/> <sup>4</sup> Broad 95% CI for pooled effect (RR 0.03‐0.94) but always below 1.<br/> <sup>5</sup> Broad 95% CI ranging from less to more adverse events with prophylaxis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005590-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study quality assessment criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concealment C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generation C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central randomisation in a multi‐center trial or randomisation in pharmacy in a single centre trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No description of methods used for allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any method resulting in a truly random sequence (computer‐generated list, coin tossing, other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No description of methods used for allocation generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of case record numbers, patient identification or admission numbers</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐numbered or coded identical containers administered serially to patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not allocation concealment A or C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of case record numbers, patient identification or admission numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not allocation generation A or C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomisation based on patient's room number</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sequentially numbered, sealed, opaque envelopes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open randomisation lists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computer file accessed only after patient's recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of birth date or admission day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study quality assessment criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/full#CD005590-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005590-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TMP/SMX versus placebo, no treatment or non‐PCP drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Documented PCP infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.10, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.14, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.09, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Documented PCP infections ‐ solid organ transplant subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.02, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Documented PCP infections ‐ hematological cancer subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.02, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.02, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Documented PCP infections ‐ adults vs. children <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.04, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.28, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.17, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.02, 10.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PCP‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.03, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bacterial infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.21, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.80, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any infections other than PCP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.14, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.66 [2.55, 8.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: requiring temporary or permanent treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.36, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [1.11, 13.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: severe adverse events requiring treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.05, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [0.80, 26.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.09, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.94 [1.35, 11.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 TMP/SMX vs. placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.84, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 TMP/SMX vs. other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.18, 20.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TMP/SMX versus placebo, no treatment or non‐PCP drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005590-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuous daily versus thrice weekly TMP‐SMX</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Documented PCP infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PCP‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: requiring temporary or permanent treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: severe adverse events requiring treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.23, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: leukopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.60, 13.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any infections other than PCP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.58, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Bacterial infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.66, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuous daily versus thrice weekly TMP‐SMX</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005590.pub3/references#CD005590-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005590.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005590-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005590-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD005590-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD005590-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005590-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005590\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005590\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005590\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005590\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005590\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005590.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005590.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005590.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005590.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005590.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724419665"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005590.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724419669"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005590.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e62609fc7f3fd',t:'MTc0MDcyNDQxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 